Pieter Droppert

Pieter Droppert is a management consultant, lawyer, science writer and editor of the Biotech Strategy Blog (http://biotechstrategyblog.com) on science, innovation and new product development in the pharma & biotech industries.

Recent posts

A Revolution is Taking Place in the Treatment of Blood Cancers
I try to avoid sensationalizing early clinical trial results presented at medical conferences, what’s commonly known as “hype over hope.” But at this year’s annual meeting of the American Society of... Read more »
Is Crowdfunding The Future For Biomedical Research?
Microryza.com (not the catchiest of names) is a crowdfunding platform for research that raises money over the Internet from individuals who are willing to donate small amounts to fund a specific... Read more »
Prostate Cancer Drug Winners and Losers at ASCO GU
The latest clinical research in prostate cancer is being presented at the American Society of Clinical Oncology Genitorinary Cancers Symposium (ASCO GU) in Orlando, FL. Presentations started yesterday, and run through... Read more »
Emerging Challenges of Prostate Cancer Drug Development
The world’s largest cancer meeting of scientists, physicians and industry has just ended in Chicago. The annual meeting of the American Society of Clinical Oncology (ASCO) attracted over 30,000 attendees to... Read more »
J&J Prostate Cancer Trial Shouldn’t Have Been Stopped Early
One of the more anticipated clinical trials at this year’s American Society of Clinical Oncology (ASCO) meeting was for Johnson & Johnson’s abiraterone (Zytiga) in prostate cancer patients. This study, known... Read more »

Page 1 of 1

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Decentralized Clinical Trials: The Call for a New Paradigm
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

Sponsored · Video
The Bay Area and Beyond: Biocom Talks Innovation and COVID
A Fireside Chat with Biocom President & CEO Joe Panetta
Biocom

Xconomy on Demand

We offer a number of ways to subscribe for free!

Subscribe Now

Xconomy National

Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More

CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears

Seres Sets Sights on FDA After C. Diff Microbiome Therapy Scores in Phase 3

Last Chance for Xconomy Awards Nominations - Deadline is Friday, July 17

Last Chance for Xconomy Awards Nominations - Deadline is Friday, July 17

Last Chance for Xconomy Awards Nominations - Deadline is Friday, July 17

Advisory Body Backs MesoBlast Therapy for Transplant Complication

Last Chance for Xconomy Awards Nominations - Deadline is Friday, July 17

G1 Vets Launch Arc Therapeutics to Take on New Cancer Target

Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup

Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia

Last Chance for Xconomy Awards Nominations - Deadline is Friday, July 17

Last Chance for Xconomy Awards Nominations - Deadline is Friday, July 17

Last Chance for Xconomy Awards Nominations - Deadline is Friday, July 17

Mallinckrodt’s Kidney Failure Drug Narrowly Wins Backing of FDA Panel

Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing

Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology

The Xcelerate Keynote Series – Part of Biotech Week Boston

The 2020 National Xconomy Awards

Xcelerating Life Sciences Seattle

Xcelerating Life Sciences New York

Pieter Droppert

Recent posts

A Revolution is Taking Place in the Treatment of Blood Cancers

Is Crowdfunding The Future For Biomedical Research?

Prostate Cancer Drug Winners and Losers at ASCO GU

Emerging Challenges of Prostate Cancer Drug Development

J&J Prostate Cancer Trial Shouldn’t Have Been Stopped Early

Underwriters and Partners

Decentralized Clinical Trials: The Call for a New Paradigm

How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook

The Bay Area and Beyond: Biocom Talks Innovation and COVID

Xconomy on Demand

We offer a number of ways to subscribe for free!